![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
St. Jude Children's Research Hospital National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00085202 |
RATIONALE: Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. It is not yet known which radiation therapy regimen combined with chemotherapy and donor stem cell transplant is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor.
PURPOSE: This phase III trial is studying two different regimens of radiation therapy when given together with chemotherapy and autologous stem cell transplant to see how well they work in treating patients with newly diagnosed medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor.
Condition | Intervention | Phase |
---|---|---|
Brain and Central Nervous System Tumors |
Drug: cisplatin Drug: cyclophosphamide Drug: filgrastim Drug: vincristine sulfate Procedure: autologous hematopoietic stem cell transplantation Procedure: radiation therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor |
Estimated Enrollment: | 164 |
Study Start Date: | August 2003 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Stratum 1 (high-risk group): Experimental
Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.
|
Drug: cisplatin
Given IV
Drug: cyclophosphamide
Given IV
Drug: filgrastim
Given subcutaneously
Drug: vincristine sulfate
Given IV
Procedure: autologous hematopoietic stem cell transplantation
Patients undergo autologous stem cell transplantation
Procedure: radiation therapy
Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
|
Stratum 2 (average-risk group): Experimental
Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.
|
Drug: cisplatin
Given IV
Drug: cyclophosphamide
Given IV
Drug: filgrastim
Given subcutaneously
Drug: vincristine sulfate
Given IV
Procedure: autologous hematopoietic stem cell transplantation
Patients undergo autologous stem cell transplantation
Procedure: radiation therapy
Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to disease risk (high-risk disease vs average-risk disease).
Patients in both strata undergo peripheral blood stem cell or bone marrow harvest.
Stratum 1 (high-risk group):
Stratum 2 (average-risk group):
Some patients undergo a neuropsychology assessment at baseline, before chemotherapy, and then annually for 5 years.
After completion of study therapy, patients are followed every 3 months until month 30 (2.5 years) after diagnosis and then every 6 months until month 72 (6 years) after diagnosis.
PROJECTED ACCRUAL: A total of 164 patients will be accrued for this study within 5.5 years.
Ages Eligible for Study: | 3 Years to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Meets one of the following risk criteria:
Average-risk disease
T4 disease eligible if all of the following are true:
High-risk disease meeting one of the following criteria:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, North Carolina | |
Duke Comprehensive Cancer Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Clinical Trials Office - Duke Comprehensive Cancer Center 888-275-3853 | |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Michael Fisher, MD 215-590-3025 | |
United States, Tennessee | |
St. Jude Children's Research Hospital | Recruiting |
Memphis, Tennessee, United States, 38105 | |
Contact: Clinical Trials Office - St. Jude Children's Research Hospital 901-495-4644 | |
United States, Texas | |
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital | Recruiting |
Houston, Texas, United States, 77030-2399 | |
Contact: Murali M. Chintagumpala, MD 832-822-4266 | |
Australia, New South Wales | |
Children's Hospital at Westmead | Recruiting |
Westmead, New South Wales, Australia, 2145 | |
Contact: Stewart J. Kellie, MD 61-2-9845-2141 stewartk@chw.edu.au | |
Sydney Children's Hospital | Recruiting |
Randwick, New South Wales, Australia, 2031 | |
Contact: Richard Cohn, FRACP 61-2-9382-1730 r.cohn@unsw.edu.au | |
Australia, Queensland | |
Royal Children's Hospital | Recruiting |
Brisbane, Queensland, Australia, 4029 | |
Contact: Tim Hassall, MBBS, FRACP 61-7-3636-9115 tim_hassall@health.qld.gov.au | |
Australia, Victoria | |
Royal Children's Hospital | Recruiting |
Parkville, Victoria, Australia, 3052 | |
Contact: David Ashley, MBBS, FRACP, PhD 61-39-345-5652 | |
Canada, Ontario | |
Hospital for Sick Children | Recruiting |
Toronto, Ontario, Canada, M5G 1X8 | |
Contact: Eric Bouffet, MD, MRCP 416-813-8024 eric.bouffet@sickkids.ca |
Principal Investigator: | Amar Gajjar, MD | St. Jude Children's Research Hospital |
Responsible Party: | St. Jude Children's Research Hospital ( Amar Gajjar ) |
Study ID Numbers: | CDR0000367486, SJCRH-SJMB03 |
Study First Received: | June 10, 2004 |
Last Updated: | January 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00085202 |
Health Authority: | Unspecified |
untreated childhood medulloblastoma untreated childhood supratentorial primitive neuroectodermal tumor childhood atypical teratoid/rhabdoid tumor untreated childhood pineoblastoma |
Neuroectodermal Tumors, Primitive Rhabdoid Tumor Vincristine Central Nervous System Neoplasms Cyclophosphamide Rhabdoid tumor Neuroectodermal Tumors |
Cisplatin Neoplasms, Germ Cell and Embryonal Medulloblastoma Neuroepithelioma Glioma Nervous System Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Mitosis Modulators Neoplasms, Nerve Tissue Nervous System Diseases Physiological Effects of Drugs Antimitotic Agents Immunosuppressive Agents Pharmacologic Actions |
Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Myeloablative Agonists Antineoplastic Agents, Alkylating Neoplasms, Neuroepithelial Antirheumatic Agents Antineoplastic Agents, Phytogenic Alkylating Agents Neoplasms, Complex and Mixed |